In drug delivery, nobody claps for the pump until the pump is the line between “today” and “not today.” Quiet hardware. Loud outcomes. That is where EMED Technologies Corporation operates out of El...
In drug delivery, nobody claps for the pump until the pump is the line between “today” and “not today.” Quiet hardware. Loud outcomes. That is where EMED Technologies Corporation operates out of El Dorado Hills, California, building mechanical subcutaneous infusion systems for real life. Home. Ambulatory care. Rooms with pets, noise, and zero tolerance for fragile tech.
EMED’s subsidiary just closed an $8M equity round led by an undisclosed multibillion dollar healthcare company. I respect the silence. When a strategic writes the check and skips the spotlight, that is not branding, that is belief. Capital talks. Conviction barely raises its voice.
Congratulations to CEO Paul Lambert and the entire EMED team, including the CTO not named in the announcement, the one translating “expansion” into tolerances, tooling, validation, and repeatability. In med devices, physics keeps the receipts.
EMED is not selling a dream. EMED is selling flow. SCIg60. VersaPump. Infusion sets and flow rate controllers that do not need a wall outlet or a software patch to perform. Mechanical syringe pump systems built for mid to large volume subcutaneous biologics and specialty drugs, including immunoglobulin therapy, delivered with consistency that turns treatment from disruption into routine.
The press language is measured: scale the organization, expand the product line, strengthen the balance sheet, stay flexible. For operators, that means grow without cracking, innovate without drifting, and serve 100,000s of patients who care less about valuation and more about reliability.
Clinical credibility is not an accessory. Alex Nikanorov, M.D., Ph.D., leads as Director of Clinical Affairs, backed by a Scientific Advisory Board that includes Dr. Jeffrey Allen, Dr. Richard Wasserman, and Dr. Jack Lewin. That is not window dressing. That is preparation for what comes next.
For founders watching, this is the pattern. Strategic capital flows to platforms that already work, governance that looks institutional, and infrastructure that can carry scale. Focus wins. Discipline compounds.
If you operate in infusion therapy, specialty pharmacy, or home health, where subcutaneous delivery is the job, not a feature, what shifts when the pump stops demanding electricity and starts acting like the most dependable presence in the room?